Northwest Biotherapeutics (NWBO) Debt Ratio (2010 - 2026)

Northwest Biotherapeutics' Debt Ratio history runs 17 years deep, the most recent figure standing at 0.09 for Q1 2026.

• In Q1 2026, Debt Ratio fell 85.04% year-over-year to 0.09; the TTM figure through Mar 2026 stood at 0.09 (down 85.04% YoY), while the FY2025 annual figure was 0.27, down 67.46% from the prior year.
• Debt Ratio for Q1 2026 stood at 0.09, down from 0.27 in the prior quarter.
• The five-year high for Debt Ratio was 1.06 in Q4 2023, with the low at 0.09 in Q1 2026.
• The 5-year median for Debt Ratio is 0.68 (2024), against an average of 0.68.
• The sharpest annual moves came in 2023 and 2026: Debt Ratio jumped 126.22% in 2023, then sank 85.04% in 2026.
• Northwest Biotherapeutics' Debt Ratio stood at 0.47 in 2022, then surged by 126.22% to 1.06 in 2023, then fell by 22.34% to 0.82 in 2024, then plunged by 67.46% to 0.27 in 2025, then sank by 66.36% to 0.09 in 2026.
• Business Quant data shows NWBO's Debt Ratio at 0.09 in Q1 2026, 0.27 in Q4 2025, and 0.55 in Q3 2025.